Sporadic ccRCC is commonly treated with inhibitors of the vascular endothelial growth factor (VEGF) signaling pathway, which results in a prolongation of disease progression and overall survival by only a few months (Rini and Atkins, 2009). The gene discussed is VEGFA; the disease is nonpapillary renal cell carcinoma.